Melanoma: Clinical Updates and Perspectives

Dear Colleagues,

In recent years, major advances have been made in the diagnosis and treatment of melanoma, leading to an improvement in the overall survival rate of melanoma patients. Early and accurate diagnosis is crucial to improving clinical outcomes, as an early misdiagnosis can significantly reduce a patient’s chance of survival. The development of dermoscopy, confocal microscopy and other non-invasive techniques helps dermatologists diagnose early melanoma, although none of these techniques are 100% accurate. On the other hand, systems based on artificial intelligence (AI), particularly deep learning, are being increasingly studied, as the use of AI might lead to more precise and faster diagnoses.

Advances in our understanding of the pathophysiology of melanoma have enabled the identification of its implications in terms of clinical features and the development of therapy. Immune checkpoint therapy and targeted therapy have changed melanoma prognosis, although the ineffectiveness of therapeutic measures suggests that much remains to be understood about the mechanism of response and resistance to these drugs. Detecting molecular markers, such as genetic or immune alterations, has emerged as an innovative diagnostic and prognostic prediction method that guides therapeutic decisions.

The aim of this Special Issue is to highlight recent advances in the context of the diagnosis, treatment and prediction of the prognosis for melanoma.

Dr. Loredana Ungureanu
Dr. Simona C. Şenilǎ
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• melanoma
• diagnosis
• prognosis
• therapy
• perspectives